The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives

BACKGROUND: Natalizumab is a recombinant humanized monoclonal antibody (mAb) against α4-integrin that is approved for relapsing forms of multiple sclerosis (MS). Natalizumab is associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML), and with disease reactiva...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Rehana Z, Sguigna, Peter V, Okai, Annette, Wright, Crystal, Madinawala, Mariam, Bass, Ann D, Cutter, Gary R, Manouchehri, Navid, Stuve, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434668/
https://www.ncbi.nlm.nih.gov/pubmed/36062026
http://dx.doi.org/10.1177/11795735221123911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434668/
https://www.ncbi.nlm.nih.gov/pubmed/36062026
http://dx.doi.org/10.1177/11795735221123911

Ejemplares similares